VivoSim Secures First Commercial Sales in China for NAMkind Testing Services
VivoSim (NASDAQ:VIVS) has reported its first commercial sales in mainland China through two paid customer engagements, marking a significant expansion of its drug testing platform into one of the world's largest pharmaceutical markets. The contracts cover gastrointestinal toxicology screening and efficacy profiling for oncology and other disease areas.
Topics: International Market Entry Non-Animal Models (NAMkind) Pharmaceutical Testing